ConductScience.org, home

Trial · NCT06556810

Registered outcomes18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimarySafety of IC14 treatment0-28 dayssafety measured by treatment-emergent adverse events, including abnormal laboratory values
PrimaryAnti-Drug Antibodies following IC14 treatment0-28 daysanti-drug antibodies
SecondaryC-reactive protein, biomarker of inflammationbaseline, 24 hours, 72 hours or discharge, Day 10, Day 29area under the curve (0 \[normal\]; 1-10 mg/dL \[moderate elevation\]; \> 10 mg/dL \[marked elevation\] per time)
SecondaryB-type natriuretic peptide, biomarker of heart failurebaseline, 24 hours, 72 hours or discharge, Day 10, Day 29absolute value (\<100 pg/mL \[normal\], \>=100 pg/mL \[heart failure\])
SecondaryEstimated glomerular filtration rate, biomarker of heart failurebaseline, 72 hours or discharge, Day 10, Day 29absolute value(\>=90 ml/min/1.73 m2 \[normal\]; 60-89 \[possible impairment\]; 15-59 \[impairment\]; \<15 \[renal failure\])
SecondaryUrine sodiumbaseline, 24 hours, 72 hours or dischargeabsolute value (40-220 milliequivalents/day)
SecondaryDyspnea Visual Analogue Scalebaseline, 24 hours, 72 hours, Day 10, Day 29, and 3 months (virtual).10-cm Visual Analogue Scale
SecondaryCongestion Scorebaseline, 24 hours, 72 hours, Day 10, and Day 29a composite score of one point for peripheral edema, jugular venous distension ≥10 cm, pulmonary rales, or S3 gallop (0 \[good\] to 4 \[poor\])
SecondaryLoop diuretic requirementduring the first 72 hours of hospitalizationtotal loop diuretic requirement (in furosemide equivalents) as calculated from concomitant medication listings
SecondaryDoppler echocardiogrambaseline, Day 10Change from baseline in left ventricular ejection fraction (left ventricular ejection fraction (\>52% male, \>54% female \[normal\])
SecondaryEchocardiogrambaseline, Day 10Change from baseline in left ventricular global longitudinal strain (normal 21%)
SecondaryNon-invasive hemodynamic assessmentbaseline, 24 hours, 72 hours, Day 1Measure of cardiac output
SecondaryBioimpedance analysisbaseline, 24 hours, 72 hours, Day 1Measure of extracellular fluid as a marker of heart failure
SecondaryCardiopulmonary exercise testDay 10aerobic exercise capacity (peak oxygen consumption \[VO2\]; \<30 mL/kg/min \[sedentary\])
SecondaryPharmacokinetic determination of half-life, maximum concentration and area-under-the-curvebaseline, 15 minutes, 6 hours, 24 hours, 72 hours, Day 10, Day 29serum IC14 level
SecondaryPharmacodynamicsDay 10, Day 29Duration of monocyte CD14 receptor occupancy \>90%
SecondaryEx-vivo leukocyte release assayDay 10Lipopolysaccharide-stimulated release of interleukin 6
SecondaryKansas City Cardiomyopathy Questionnairebaseline to 3 months
Questionnaire for the patient that reports on 23 aspects of how heart failure affects the patient's life (0\[worst symptoms/limitations\]-100\[least symptoms/limitations and excellent quality of life\])

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06556810/registered